1
|
Wang IC, Lin JH, Lee WS, Liu CH, Lin TY, Yang KT. Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocytes. Int J Cardiol 2023; 375:74-86. [PMID: 36513286 DOI: 10.1016/j.ijcard.2022.12.018] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2022] [Revised: 11/23/2022] [Accepted: 12/08/2022] [Indexed: 12/14/2022]
Abstract
BACKGROUND Ischemia/reperfusion (I/R) is associated with severe cellular damage and death. Ferroptosis, a new form of regulated cell death caused by the accumulation of iron-mediated lipid peroxidation, has been found in several diseases including I/R injury, which was reported to be suppressed by flavonoids. Baicalein (BAI) and luteolin (Lut) are flavonoids and were shown to reduce the myocardial I/R injury. BAI was found to suppress ferroptosis in cancer cells via reducing reactive oxygen species (ROS) generation. However, the anti-ferroptosis effect of Lut on ferroptosis has not been reported. This study aimed to investigate whether ferroptosis reduction contributes to the BAI- and Lut-protected cardiomyocytes. METHODS This research used erastin, RSL3, and Fe-SP to induce ferroptosis. Cell viability was examined using MTT assay. Annexin V-FITC, CM-H2DCFDA, and Phen Green SK diacetate (PGSK) fluorescent intensity were detected to analyze apoptotsis, ROS levels, and Fe2+ concentrations, respectively. qPCR and Western blot analysis were conducted to detect the levels of mRNA and protein, respectively. RESULTS Our data show that BAI and Lut protected cardiomyocytes against ferroptosis caused by ferroptosis inducers and I/R. Moreover, both BAI and Lut decreased ROS and malondialdehyde (MDA) generation and the protein levels of ferroptosis markers, and restored Glutathione peroxidase 4 (GPX4) protein levels in cardiomyocytes reduced by ferroptosis inducers. BAI and Lut reduced the I/R-induced myocardium infarction and decreased the levels of Acsl4 and Ptgs2 mRNA. CONCLUSIONS BAI and Lut could protect the cardiomyocytes against the I/R-induced ferroptosis via suppressing accumulation of ROS and MDA.
Collapse
Affiliation(s)
- I-Chieh Wang
- Ph.D. Program in Pharmacology and Toxicology, School of Medicine, Tzu Chi University, No.701, Zhongyang Rd., Sec. 3, Hualien 97004, Taiwan.
| | - Jian-Hong Lin
- Division of Experimental Surgery, Department of Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 707, Sec. 3, Zhongyang Rd., Hualien, Taiwan.
| | - Wen-Sen Lee
- Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wuxing St., Xinyi Dist., Taipei 110301, Taiwan; Department of Physiology, School of Medicine, Tzu Chi University, No.701, Zhongyang Rd., Sec. 3, Hualien 97004, Taiwan.
| | - Chin-Hung Liu
- Department of Pharmacology, School of Medicine, Tzu Chi University, No.701, Zhongyang Rd., Sec. 3, Hualien 97004, Taiwan.
| | - Ting-Yuan Lin
- Division of Cardiology, Department of Internal Medicine, Taipei City Hospital, Renai Branch, No. 10, Sec. 4, Ren'ai Rd., Da'an Dist., Taipei 10341, Taiwan.
| | - Kun-Ta Yang
- Department of Physiology, School of Medicine, Tzu Chi University, No.701, Zhongyang Rd., Sec. 3, Hualien 97004, Taiwan.
| |
Collapse
|
2
|
Tan YQ, Lin F, Ding YK, Dai S, Liang YX, Zhang YS, Li J, Chen HW. Pharmacological properties of total flavonoids in Scutellaria baicalensis for the treatment of cardiovascular diseases. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 107:154458. [PMID: 36152591 DOI: 10.1016/j.phymed.2022.154458] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 08/21/2022] [Accepted: 09/13/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Scutellaria baicalensis, a medicinal herb belonging to the Lamiaceae family, has been recorded in the Chinese, European, and British Pharmacopoeias. The medicinal properties of this plant are attributed to the total flavonoids of Scutellaria baicalensis (TFSB), particularly the main component, baicalin. This study provides a systematic and comprehensive list of the identified TFSB components and their chemical structures. The quality control process, pharmacokinetics, clinical application, and safety of Scutellaria baicalensis are discussed, and its pharmacological effect on cardiovascular diseases (CVDs) is detailed. Finally, the future research trends and prospects of this medicinal plant are provided. METHODS The Chinese and English papers related to TFSB were collected from the PubMed and CNKI databases using the relevant keywords. To highlight the pharmacological mechanism, clinical application, and safety of TFSB, the collected articles were screened and classified based on their research content. RESULTS TFSB contains at least 100 different kinds of flavonoids, of which baicalin, baicalein, wogonin, wogonoside, scutellarin, and scutellarein are the main active ingredients. The preparation process of TFSB is relatively well established, and the extraction rate can be significantly increased by enzymatic pretreatment and ultrasonication. The low oral availability of TFSB may be effectively enhanced using nanoformulations. The available pharmacokinetic data show that flavonoid glycosides and aglycones with the same parent nucleus may be converted to structures that are conducive to absorption in vivo. Moreover, TFSB can protect against CVDs by inhibiting apoptosis, regulating oxidative stress response, participating in inflammatory response, protecting against myocardial fibrosis, inhibiting myocardial hypertrophy, and regulating blood vessels. In terms of clinical application and animal safety, the available studies show that TFSB can be applied in a wide range of clinical treatments and is safe to use is animals. CONCLUSION This article systematically reviews the therapeutic effect and underlying pharmacological mechanism of TFSB against CVDs. The available studies clearly suggest that TFSB has great potential for the treatment of CVDs and is worthy of in-depth research and development.
Collapse
Affiliation(s)
- Yu-Qing Tan
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China; Beijing University of Chinese Medicine, Beijing 100029, China
| | - Fei Lin
- The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100 Henan, China
| | - Yu-Kun Ding
- Beijing University of Chinese Medicine, Beijing 100029, China; Department of Cardiology, Dongzhimen Hospital, Beijing University of Traditional Chinese Medicine, Beijing 100700, China
| | - Shuang Dai
- Beijing University of Chinese Medicine, Beijing 100029, China
| | - Ying-Xin Liang
- Traditional Chinese Medicine Orthopedics, Liuzhou Worker's Hospital, Liuzhou 545007, China
| | - Yun-Shu Zhang
- Beijing University of Chinese Medicine, Beijing 100029, China
| | - Jun Li
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
| | - Heng-Wen Chen
- Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
| |
Collapse
|
3
|
Li J, Chang WT, Qin G, Wojcik KR, Li CQ, Hsu CW, Han M, Zhu X, Vanden Hoek TL, Shao ZH. Baicalein Preconditioning Cardioprotection Involves Pro-Oxidant Signaling and Activation of Pyruvate Dehydrogenase. THE AMERICAN JOURNAL OF CHINESE MEDICINE 2022; 50:1255-1267. [PMID: 35748215 DOI: 10.1142/s0192415x22500513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Preconditioning has a powerful protective potential against myocardial ischemia-reperfusion injury (I/R). Our prior work demonstrated that baicalein, a flavonoid derived from the root of Scatellaria baicalensis Georgi (also known as Huangqin), confers this preconditioning protection. This study further explored the mechanisms of baicalein preconditioning (BC-PC) in mouse cardiomyocytes. Cells were treated with baicalein (10 μM) for a brief period of time (10 min) prior to simulated ischemia 90 min/reperfusion for 180 min. Baicalein triggered an induction of a small amount of mitochondrial reactive oxygen species (ROS) prior to the initiation of ischemia, assessed by 6-carboxy-2', 7'-dichlorodihydrofluorescein diacetate (6-carboxy-H2DCFDA). It also significantly increased cell viability measured by propidium iodide (PI) and lactate dehydrogenase and preserved mitochondrial membrane potential assessed by TMRM fluorescence intensity. Myxothiazol, a mitochondrial electron transport chain complex III inhibitor, partially blocked ROS generation induced by BC-PC and reduced cell viability. BC-PC increased phosphorylation of Akt (Thr308 and Ser473) and eNOS Ser1177, and nitric oxide (NO) production measured using 4,5-diaminofluorescein diacetate (DAF-2 DA, 1 μM). Akt inhibitor API-2 abolished Akt phosphorylation and reduced DAF-2 production and cell viability. In addition, BC-PC decreased phosphorylation of pyruvate dehydrogenase (PDH) reflecting upregulated PDH activity, and increased ATP production at 30 min during reperfusion. Taken together, baicalein preconditioning-induced cardioprotection involves pro-oxidant generation, activates survival signaling Akt/eNOS/NO, and improves metabolic recovery after I/R injury. Our work provides new perspectives on the effect of baicalein on cardiac preconditioning against I/R injury.
Collapse
Affiliation(s)
- Jing Li
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Wei-Tien Chang
- Department of Emergency Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan
| | - Gina Qin
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Kimberly R Wojcik
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Chang-Qing Li
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Chin-Wang Hsu
- Department of Emergency, School of Medicine, College of Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
- Emergency Department, Department of Emergency and Critical Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
| | - Mei Han
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Xiangdong Zhu
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Terry L Vanden Hoek
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| | - Zuo-Hui Shao
- Department of Emergency Medicine, Center for Advanced Resuscitation Medicine, University of Illinois, Chicago, IL, USA
| |
Collapse
|
4
|
Qiao D, Xing J, Duan Y, Wang S, Yao G, Zhang S, Jin J, Lin Z, Chen L, Piao Y. The molecular mechanism of baicalein repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2022; 100:154046. [PMID: 35306368 DOI: 10.1016/j.phymed.2022.154046] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 02/20/2022] [Accepted: 03/11/2022] [Indexed: 06/14/2023]
Abstract
BACKGROUND Baicalein (BAI) has a significant anti-cancerous function in the treatment of gastric cancer (GC). Focal adhesion kinase (FAK) is a key regulatory molecule in integrin and growth factor receptor mediated signaling. MicroRNA-7 (miR-7), has been considered as a potential tumor suppressor in a variety of cancers. However, the possible mechanisms by which BAI inhibiting progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway remain unclear. PURPOSE To investigate the molecular mechanism and effects of BAI inhibiting progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway. METHODS Gastric cancer cell lines with FAK knockdown and overexpression were constructed by lentivirus transfection. After BAI treatment, the effects of FAK protein on proliferation, metastasis and angiogenesis of gastric cancer cells were detected by MTT, EdU, colony formation, wound healing, transwell and Matrigel tube formation assays. In vivo experiment was performed by xenograft model. Immunofluorescence and western blot assay were used to detect the effects of FAK protein on the expression levels of EMT markers and PI3K/AKT signaling pathway related proteins. qRT-PCR and luciferase reporter assay were used to clarify the targeting relationship between miR-7 and FAK. RESULTS BAI can regulate FAK to affect proliferation, metastasis and angiogenesis of gastric cancer cells through PI3K/AKT signaling pathway. qRT-PCR showed BAI can upregulated the expression of miR-7 and luciferase reporter assay showed the targeting relationship between miR-7 and FAK. Additionally, miR-7 mediates cell proliferation, metastasis and angiogenesis by directly targeting FAK 3'UTR to inhibit FAK expression. CONCLUSION BAI repressing progression of gastric cancer mediating miR-7/FAK/AKT signaling pathway.
Collapse
Affiliation(s)
- Dan Qiao
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Jian Xing
- Department of Image, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang 157011, P.R. China
| | - Yunxiao Duan
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Shiyu Wang
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Guangyuan Yao
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Shengjun Zhang
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Jingchun Jin
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China; Department of Internal Medicine of Yanbian University Hospital, Yanji 133000, P.R. China
| | - Zhenhua Lin
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China; Department of Internal Medicine of Yanbian University Hospital, Yanji 133000, P.R. China
| | - Liyan Chen
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China
| | - Yingshi Piao
- Cancer Research Center, Yanbian University Medical College, Key Laboratory of Pathobiology (Yanbian University), State Ethnic Affairs Commission, Research and Innovation Group of Yanbian University, Yanji, P.R. China.
| |
Collapse
|
5
|
Qiao D, Jin J, Xing J, Zhang Y, Jia N, Ren X, Lin Z, Jin N, Chen L, Piao Y. Baicalein Inhibits Gastric Cancer Cell Proliferation and Migration through a FAK Interaction via AKT/mTOR Signaling. THE AMERICAN JOURNAL OF CHINESE MEDICINE 2021; 49:525-541. [PMID: 33641654 DOI: 10.1142/s0192415x21500245] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Gastric cancer is a common malignancy worldwide and is associated with high morbidity and mortality rates. However, very little is known about the underlying mechanism in human gastric cancer cells. Baicalein (BAI), a widely used Chinese herbal medicine, has shown anticancer effects on many types of human cancer cell lines. Here, we investigated the molecular mechanisms underlying BAI action on gastric cancer cell proliferation and migration. The results showed that BAI can expressively inhibit cell proliferation, colony-forming ability and migration ability in a dose-dependent manner, while in the meantime inducing cell apoptosis. Additionally, we found that BAI can suppress FAK and the phosphorylation of PI3K, AKT and mTOR in a dose-dependent manner. Furthermore, BAI significantly inhibited tumor growth in a xenograft model. Also, BAI can inhibit the proliferation and migration of gastric cancer cells and the expression of the pathway by downregulating the expression of FAK. In short, we demonstrated that BAI inhibited gastric cancer cell proliferation and migration through FAK interaction via downregulation in AKT/mTOR signaling, which signifies that BAI may be a latent therapeutic factor for the treatment of gastric cancer patients and that FAK might be a hopeful therapy target for the disease.
Collapse
Affiliation(s)
- Dan Qiao
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China
| | - Jingchun Jin
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China.,Department of Internal Medicine of Yanbian University Hospital, Yanji 133000, P. R. China
| | - Jian Xing
- Department of Image, Hongqi Hospital of Mudanjiang Medical University, Mudanjiang 157011, P. R. China
| | - Yingying Zhang
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China
| | - Nailing Jia
- Department of Internal Medicine of Yanbian University Hospital, Yanji 133000, P. R. China
| | - Xiangshan Ren
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China
| | - Zhenhua Lin
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China.,Department of Internal Medicine of Yanbian University Hospital, Yanji 133000, P. R. China
| | - Ningyi Jin
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China.,Institute of Military Veterinary Medicine, Academy of Military Medical Science, Changchun 130122, P. R. China
| | - Liyan Chen
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China
| | - Yingshi Piao
- Key Laboratory of the State Ethnic Affairs Commission, Key Laboratory of Science and Technology Department (Jilin Province), Cancer Research Center, Yanbian University Medical College, Yanji 133002, P. R. China
| |
Collapse
|
6
|
Ren M, Zhao Y, He Z, Lin J, Xu C, Liu F, Hu R, Deng H, Wang Y. Baicalein inhibits inflammatory response and promotes osteogenic activity in periodontal ligament cells challenged with lipopolysaccharides. BMC Complement Med Ther 2021; 21:43. [PMID: 33485352 PMCID: PMC7824944 DOI: 10.1186/s12906-021-03213-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 01/10/2021] [Indexed: 12/13/2022] Open
Abstract
Background Periodontitis is a chronic infection initiated by oral bacterial and their virulence factors, yet the severity of periodontitis is largely determined by the dysregulated host immuno-inflammatory response. Baicalein is a flavonoid extracted from Scutellaria baicalensis with promising anti-inflammatory properties. This study aims to clarify the anti-inflammatory and osteogenic effects of baicalein in periodontal ligament cells (PDLCs) treated with lipopolysaccharides (LPS). Methods Human PDLCs were incubated with baicalein (0–100 μM) for 2 h prior to LPS challenge for 24 h. MTT analysis was adopted to assess the cytoxicity of baicalein. The mRNA and protein expression of inflammatory and osteogenic markers were measured by real-time polymerase chain reaction (PCR), western blot and enzyme-linked immunosorbent assay (ELISA) as appropriate. Alkaline phosphatase (ALP) and Alizarin red S (ARS) staining were performed to evaluate the osteogenic differentiation of PDLCs. The expression of Wnt/β-catenin and mitogen-activated protein kinase (MAPK) signaling related proteins was assessed by western blot. Results MTT results showed that baicalein up to 100 μM had no cytotoxicity on PDLCs. Baicalein significantly attenuated the inflammatory factors induced by LPS, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), matrix metalloprotein-1 (MMP-1), MMP-2 and monocyte chemoattractant protein 1 (MCP-1) at both mRNA and protein level. Moreover, MAPK signaling (ERK, JNK and p38) was significantly inhibited by baicalein, which may account for the mitigated inflammatory response. Next, we found that baicalein effectively restored the osteogenic differentiation of LPS-treated PDLCs, as shown by the increased ALP and ARS staining. Accordingly, the protein and gene expression of osteogenic markers, namely runt-related transcription factor 2 (RUNX2), collagen-I, and osterix were markedly upregulated. Importantly, baicalein could function as the Wnt/β-catenin signaling activator, which may lead to the increased osteoblastic differentiation of PDLCs. Conclusions With the limitation of the study, we provide in vitro evidence that baicalein ameliorates inflammatory response and restores osteogenesis in PDLCs challenged with LPS, indicating its potential use as the host response modulator for the management of periodontitis. Supplementary Information The online version contains supplementary material available at 10.1186/s12906-021-03213-5.
Collapse
Affiliation(s)
- Manman Ren
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Ya Zhao
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zhiqi He
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Jian Lin
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Chuchu Xu
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Fen Liu
- Department of Histology and Embryology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Rongdang Hu
- Department of Orthodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Hui Deng
- Department of Periodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Yi Wang
- Department of Orthodontics, School of Stomatology, Wenzhou Medical University, Wenzhou, Zhejiang, China.
| |
Collapse
|
7
|
Chen Y, Zhou B, Yu Z, Yuan P, Sun T, Gong J, Zhang Y, Wang T, Wang S, Liu K, Liu J. Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. J Sex Med 2020; 17:1434-1447. [PMID: 32586748 DOI: 10.1016/j.jsxm.2020.04.390] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 04/23/2020] [Accepted: 04/28/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND Management of diabetes mellitus induced-erectile dysfunction (DMED) is challenging because of its poor responses to phosphodiesterase type 5 inhibitors. Increasingly important roles of 12-lipoxygenase (12-LOX) have been proven in diabetes mellitus. AIM To investigate 12-LOX activity and therapeutic effect of its inhibitor, baicalein (BE), on DMED. METHODS Intraperitoneal streptozotocin injection was used to induce type I DM, and an apomorphine test was used to evaluate erectile function. In experiment A, we assessed 12-LOX expression alteration in the corpus cavernosum (CC) of rats with DMED of different levels of severity. In experiment B, rats with DMED were intraperitoneally injected with BE for 4 weeks, and control rats were injected with vehicles. The erectile function was tested by cavernous nerve stimulation before penile tissue was harvested. We performed Western blot, immunohistochemistry, immunofluorescence, Masson trichrome staining, and enzyme-linked immunosorbent assays to measure related proteins in CC. MAIN OUTCOME MEASURE The main outcome measures included rectile response, histologic examination, and expression alteration of related proteins. RESULTS 12-LOX upregulation was associated with the progression of type I DMED. After 4 weeks treatment, compared with the DMED group, the DMED + BE group showed better erectile responses to cavernous nerve stimulation. In the DMED + BE group, significantly enhanced endothelial nitric oxide synthase/nitric oxide/cyclic guanosine monophosphate pathway, reduced 12-LOX expression, and inhibited p38 mitogen-activated protein kinase/arginase II/L-arginine pathway were showed in CC relative to the DMED group. In addition, overactivated oxidative stress and fibrosis in the DMED group were both partially ameliorated in the DMED + BE group. CLINICAL IMPLICATIONS BE may be considered as an effective therapy for DMED, but needs to be verified in future human investigations. STRENGTHS & LIMITATIONS The role of 12-LOX and its inhibitor, BE, is firstly demonstrated in rats with type I DMED. However, the experimental data are derived from animal models with without evidences from cellular-based experiments. CONCLUSION 12-LOX might serve as an important factor in the pathogenesis of type I DMED. BE alleviated erectile dysfunction in rats with type I DMED probably by inhibiting 12-LOX expression, ameliorating endothelial nitric oxide synthase dysfunction, as well as suppressing oxidative stress and fibrosis. Chen Y, Zhou B, Yu Z, et al. Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. J Sex Med 2020;17:1434-1447.
Collapse
Affiliation(s)
- Yinwei Chen
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Bingyan Zhou
- Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Zhe Yu
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Penghui Yuan
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Taotao Sun
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Jianan Gong
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Yan Zhang
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Tao Wang
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Shaogang Wang
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Kang Liu
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
| | - JiHong Liu
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
| |
Collapse
|